Status:
COMPLETED
Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure
Lead Sponsor:
University of Leipzig
Collaborating Sponsors:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Statin therapy has been shown to efficiently reduce mortality in patients with coronary artery disease and myocardial infarction, partially as a result of the lipid-lowering properties of statins. How...
Detailed Description
A total of 40 patients with severe chronic heart failure are prospectively randomized to either 3 months of rosuvastatin or placebo treatment. Before and after the intervention period maximal exercis...
Eligibility Criteria
Inclusion
- chronic heart failure (NYHA class III or IV)
- peak oxygen uptake \<20 mL/min/kg body weight
- left ventricular ejection fraction \<30 %
- left ventricular end-diastolic diameter \>55 mm
- stable medication within the last 4 weeks
Exclusion
- elevated GOT and GPT levels as a sign of hepatic dysfunction
- elevated creatinine levels as a sign of renal dysfunction
- insulin-dependent diabetes mellitus
- arterial hypertension
- muscle disease or elevated CK levels
- treatment with fibrates
- co-treatment with drugs that are metabolized by Cyp3A4
- diseases that disallow a participation in the study
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00176332
Start Date
March 1 2004
End Date
December 1 2006
Last Update
August 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Leipzig, Heart Center, Department of Internal Medicine / Cardiology
Leipzig, Saxony, Germany, 04289